➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Mallinckrodt
McKinsey
Harvard Business School
McKesson

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LEVOCETIRIZINE DIHYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for levocetirizine dihydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00150761 Facial Thermography Study of Levocetirizine Versus Cetirizine Completed UCB Pharma Phase 4 2004-07-01 Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.
NCT00152412 Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis Completed UCB Pharma Phase 2 2004-06-01 4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years) suffering from allergic rhinitis. As secondary objective, this study will assess the efficacy of the treatment by means of the T4SS (Total 4 symptoms scores of allergic rhinitis) and each of the 4 individual rhinitis symptom scores
NCT00152464 Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM) Completed UCB Pharma Phase 3 2002-03-01 The Early Prevention of Asthma in Atopic Children (EPAAC™) . 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
NCT00160537 POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis) Completed UCB Pharma Phase 4 2005-05-01 Comparative study on clinical efficacy and safety of levocetirizine and desloratadine as measured by the subject's satisfaction/dissatisfaction after one week of treatment
NCT00160563 Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464) Terminated UCB Pharma Phase 3 2004-06-01 Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic children.
NCT00160589 LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis) Completed UCB Pharma Phase 4 2005-04-01 Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
NCT00160680 ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life) Completed UCB Pharma Phase 4 2005-03-01 Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for levocetirizine dihydrochloride

Condition Name

Condition Name for levocetirizine dihydrochloride
Intervention Trials
Allergic Rhinitis 12
Rhinitis 6
Rhinitis, Allergic, Seasonal 6
Urticaria 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for levocetirizine dihydrochloride
Intervention Trials
Rhinitis 36
Rhinitis, Allergic 32
Urticaria 12
Rhinitis, Allergic, Perennial 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for levocetirizine dihydrochloride

Trials by Country

Trials by Country for levocetirizine dihydrochloride
Location Trials
United States 69
Spain 7
Germany 6
India 5
France 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for levocetirizine dihydrochloride
Location Trials
Tennessee 4
Texas 4
Oklahoma 4
Georgia 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for levocetirizine dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for levocetirizine dihydrochloride
Clinical Trial Phase Trials
Phase 4 27
Phase 3 17
Phase 2 4
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for levocetirizine dihydrochloride
Clinical Trial Phase Trials
Completed 53
Enrolling by invitation 2
Unknown status 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for levocetirizine dihydrochloride

Sponsor Name

Sponsor Name for levocetirizine dihydrochloride
Sponsor Trials
UCB Pharma 30
GlaxoSmithKline 5
Hanmi Pharmaceutical Company Limited 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for levocetirizine dihydrochloride
Sponsor Trials
Industry 52
Other 18
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Mallinckrodt
Medtronic
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.